A large analysis looked at 648 patients with metastatic castration-resistant prostate cancer who received lutetium-177-PSMA therapy. Researchers examined whether new lesions seen on post-treatment scans predicted how long patients lived. The study found that emerging new lesions were associated with worse overall survival. Specifically, patients with these new spots had a 2.78 times higher risk of death compared to those without them. The confidence interval for this finding was 1.91 to 4.06, indicating a strong statistical link. This analysis combined data from multiple sources to provide a clearer picture of what these scans might mean for patient outcomes. The researchers noted that standardizing how these scans are read and validating findings in future prospective studies are needed before this can be fully integrated into clinical practice. Until then, the presence of new lesions should be viewed as a warning sign rather than a definitive cause of death.
Meta-analysis associates emerging lesions after lutetium-177 therapy with worse overall survival in mCRPCEmerging lesions on scans linked to lower survival in prostate cancer patients
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Note that emerging lesions after lutetium-177 therapy are associated with worse survival in mCRPC, pending validation.
This systematic review and meta-analysis synthesized data regarding interim post-treatment SPECT/CT imaging following lutetium-177 (177Lu)-PSMA therapy. The review focused on patients with metastatic castration-resistant prostate cancer, encompassing a total sample size of 648 patients. Primary outcomes included overall survival and PSA-progression-free survival. The specific setting was not reported in the source documentation provided.
The analysis clearly identified that emerging new lesions were associated with worse overall survival. The reported effect size indicated a hazard ratio of 2.78, with a 95% confidence interval of 1.91–4.06. No data were reported regarding PSA-progression-free survival outcomes in the provided summary.
The authors acknowledge that standardization and prospective validation are needed to integrate it into clinical practice. Follow-up duration was not reported in the source material. Safety data, including adverse events and discontinuations, were not reported. Funding or conflicts were not reported. The lack of reported safety data limits the assessment of tolerability.
Clinicians should interpret these findings cautiously given the observational nature of the underlying data synthesis. Prospective validation is currently required to establish utility. Current evidence does not support definitive causal claims regarding lesion emergence.
Further studies are needed to confirm these associations in future research. Integration into clinical practice requires standardization and prospective validation.
What this means for you:
New spots on scans after lutetium-177-PSMA therapy are linked to lower survival in prostate cancer patients. More on Metastatic Castration Resistant Prostate Cancer
PSMA-targeted radioligand therapy outcomes vary by patient characteristics and disease burden in metastatic castration-resistant prostate cancer
Prior chemo and liver spread worsen outcomes for prostate cancer patients on PSMA therapy
A systematic review and meta-analysis of 4,819 patients with metastatic castration-resistant prostate cancer reveals that prior chemotherapy…
A large review of 4,819 patients found that prior chemotherapy and liver spread worsen survival. This helps doctors predict who benefits mos…
PSMA PET Parameters Predict Survival in mCRPC on Lu-PSMA-617
PSMA PET scan numbers may help predict Lu-PSMA therapy response in prostate cancer
Meta-analysis of 23 studies shows PSMA PET parameters, especially tumor volume, predict survival in mCRPC patients treated with Lu-PSMA-617.
A meta-analysis of 23 studies suggests certain PSMA PET scan measurements might help predict how patients with metastatic prostate cancer re…
Narrative review discusses LPA signaling in advanced prostate cancer
LPA signaling pathway offers new hope for advanced prostate cancer treatment
This narrative review examines lysophosphatidic acid metabolism and signaling in patients with advanced prostate cancer. The authors discuss…
A review discusses how targeting lysophosphatidic acid signaling might help patients with advanced prostate cancer, though more research is …
Enzalutamide plus radium-223 extends survival in metastatic castration-resistant prostate cancer
Adding Radium-223 to enzalutamide extends life for advanced prostate cancer patients
This phase 3 randomized controlled trial in 446 patients with metastatic castration-resistant prostate cancer compared enzalutamide plus rad…
Adding a specific bone-targeting drug to standard treatment helps men with advanced prostate cancer live longer while managing side effects …
View Original Abstract ↓
Lutetium-177 (177Lu)-PSMA radioligand therapy (RLT) is established for metastatic castration-resistant prostate cancer (mCRPC), but radiologic monitoring during the treatment lacks standardization. While interim PSMA PET/CT offers accuracy, post-treatment 177Lu-PSMA SPECT/CT provides practical advantages for early response assessment. This systematic review and meta-analysis evaluates the prognostic value of interim post-treatment SPECT/CT parameters on survival outcomes in mCRPC patients.
Following PRISMA guidelines and PICO framework, PubMed/MEDLINE, Scopus, and Google Scholar were searched up to December 2025 for studies on mCRPC patients receiving 177Lu-PSMA RLT with early post-treatment SPECT/CT. Inclusion required cohort designs reporting hazard ratios (HRs) for overall survival (OS) and PSA-progression-free survival (PSA-PFS). Data extraction included study characteristics, imaging protocols, and outcomes. Quality was assessed using the Oxford CEBM tool. Random-effects meta-analysis pooled HRs; heterogeneity (I2) and publication bias (funnel plots, Egger’s test, trim-and-fill) were evaluated.
Seven studies (648 patients) were included. Pooled HRs showed emerging new lesions associated with worse OS (HR = 2.78, 95% CI: 1.91–4.06, p
Interim 177Lu-PSMA SPECT/CT offers prognostic insights, with new lesions and TTV increases signaling poor outcomes. Standardization and prospective validation are needed to integrate it into clinical practice.
Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients
Your Blood May Signal a Deadly Clotting Crisis Before It Strikes
Related in Hematology
Acute cellular senescence facilitates tissue repair while chronic accumulation drives intestinal fibrosis in Crohn's disease
Chronic cell aging may drive scarring in Crohn's disease
This systematic review examines the role of cellular senescence in intestinal fibrosis within Crohn's disease. The authors conclude that acu…
New research reveals how the timing of cellular aging determines whether your body heals properly or develops harmful scar tissue.
FDA Approves Argatroban in Sodium Chloride for Thrombosis in HIT and PCI
FDA approves new blood thinner for patients with rare clotting disorder.
The FDA approved argatroban in sodium chloride injection for prophylaxis or treatment of thrombosis in adult patients with heparin-induced t…
The FDA approved Argatroban in Sodium Chloride injection to prevent or treat blood clots in adults with heparin-induced thrombocytopenia (HI…
FDA Approves Hympavzi (marstacimab) for Routine Prophylaxis in Hemophilia A and B Without Inhibitors
FDA approves Hympavzi to prevent bleeding in hemophilia A and B.
The FDA approved Hympavzi (marstacimab) for routine prophylaxis to prevent or reduce bleeding episodes in patients 12 years and older with h…
The FDA approved Hympavzi (marstacimab) to prevent or reduce bleeding episodes in people 12 and older with hemophilia A or B without inhibit…
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
From Other Specialties
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.
Postoperative AKI occurs in half of type A aortic dissection surgeries, meta-analysis finds
Factors Linked to Kidney Injury After Aortic Dissection Surgery
This meta-analysis of 44 studies (11,983 patients) found that 50.72% of patients undergoing surgery for Stanford type A aortic dissection de…
Over half of patients undergoing surgery for a specific type of aortic dissection develop acute kidney injury, with several risk factors ide…
Social and emotional skills training shows non-significant reductions in loneliness among children and adolescents
Social and Emotional Training Shows Promise for Youth Loneliness
This meta-analysis of 18 studies evaluated interventions targeting loneliness, including social and emotional skills training, in youth aged…
New research looks at how social and emotional skills training can help reduce feelings of loneliness in children and teenagers.